An observational study of the factor Xa inhibitors rivaroxaban and apixaban as reported to eight poison centers
HA Spiller, JB Mowry, A Aleguas Jr, JRK Griffith… - Annals of emergency …, 2016 - Elsevier
Study objective Rivaroxaban and apixaban are part of a new group of oral anticoagulants
targeting factor Xa and approved by the Food and Drug Administration in 2011 and 2012.
These oral anticoagulants are administered at fixed daily doses, without the need for
laboratory-guided adjustments. There are limited data available on supratherapeutic doses
or overdose of the oral Xa inhibitors. This study characterizes the clinical effect in patients
exposed to rivaroxaban and apixaban. Methods A retrospective study collected data from 8 …
targeting factor Xa and approved by the Food and Drug Administration in 2011 and 2012.
These oral anticoagulants are administered at fixed daily doses, without the need for
laboratory-guided adjustments. There are limited data available on supratherapeutic doses
or overdose of the oral Xa inhibitors. This study characterizes the clinical effect in patients
exposed to rivaroxaban and apixaban. Methods A retrospective study collected data from 8 …
以上显示的是最相近的搜索结果。 查看全部搜索结果